乌龙制药 2025年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedMarch 31, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UROGEN PHARMA LTD. (Exact Name of Registrant as Specified in its Charter) Israel(State or other jurisdiction ofincorporation or organization)400 Alexander Park Drive,Princeton,New Jersey(Address of principal executive offices) 98-1460746(I.R.S. EmployerIdentification No.)08540(Zip Code) (646)768-9780 Registrant’s telephone number, including area code N/A (Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuantto Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May 5, 2025, the registrant had46,107,451ordinary shares, par value NIS 0.01 per share, outstanding. UroGen Pharma Ltd.Index PART I.FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)Condensed Consolidated Balance SheetsCondensed Consolidated Statements of Operations and Comprehensive LossCondensed Consolidated Statements of Shareholders’DeficitCondensed Consolidated Statements of Cash FlowsNotes to Unaudited Condensed Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and ProceduresPART II.OTHER INFORMATIONItem 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures Trademarks and Trade Names Unless the context requires otherwise, references in this Quarterly Report to the “Company,”"UroGen," “we,” “us” and “our” referto UroGen Pharma Ltd. and its subsidiary, UroGen Pharma, Inc. UroGen®,RTGel®, andJelmyto®are trademarks of ours that we use in this Quarterly Report. This Quarterly Report alsoincludes trademarks, tradenames, and service marks that are the property of other organizations. Solely for convenience, ourtrademarks and tradenames referred to in this Quarterly Report appear without the ® or ™ symbols, but those references are notintended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of theapplicable licensor to our trademark and tradenames. We do not intend our use or display of other companies’ trade names ortrademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Part I—Financial Information UroGen Pharma Ltd.Condensed Consolidated Balance Sheets(unaudited; in thousands, except share amounts and par value) UroGen Pharma Ltd.Condensed Consolidated Statements of Operations and Comprehensive Loss(unaudited; in thousands, except share and per share amounts) For the Three Months EndedMarch 31,20252024Revenue$20,254$18,781Cost of revenue2,3301,728Gross profit17,92417,053Operating expenses:Research and development expenses19,87115,494Selling, general and administrative expenses34,96727,299Operating loss(36,914)(25,740)Financing on prepaid forward obligation(4,583)(5,660)Interest expense on long-term debt(4,068)(2,447)Interest and other income, net2,1141,615Loss before income taxes(43,451)(32,232)Income tax expense(392)(54)Net Loss$(43,843)$(32,286)Statements of Comprehensive LossNet loss$(43,843)$(32,286)Other comprehensive lossUnrealized loss on investments(42)(49)Comprehensive Loss$(43,885)$(32,335)Net loss per ordinary share - basic and diluted$(0.92)$(0.